LEADERSHIP TEAM

Susan Hill

Chief Executive Officer

Susan Hill
Chief Executive Officer
Susan Hill is Chief Executive Officer of Mestag Therapeutics. Susan joined Mestag from Gyroscope Therapeutics, where she served as Chief Business Officer and helped to drive the company’s $62m Series B. Prior, she was founding Chief Executive Officer of Orbit Biomedical ($12m Series A) and Chief Business Officer of Freeline Therapeutics. Previously, Susan served in the Business & Corporate Development team at Alexion (ALXN), and during an 8-year tenure at Merck Serono (MRK) in a series of Corporate & Business Development and Portfolio Management roles. Susan began her career in strategy consulting/M&A, followed by a 3-year tenure leading biotech seed investments. She has an MA and PhD from the University of Cambridge and is a previous Fellow of the Securities Institute.

Ray Jupp

Chief Scientific Officer

Ray Jupp
Chief Scientific Officer
Ray Jupp is the CSO of Mestag Therapeutics. Prior to this Ray was CSO of Enara Bio. Prior to joining Enara Bio, Ray was the founding CSO of TRex Bio, a discovery stage company focused on the functional manipulation of T-regulatory cells in a tissue-specific and disease-specific fashion to deliver transformative therapies for multiple disease indications. Previously, Ray was head of the Immunology/Inflammation therapeutic area at UCB where he drove multiple compounds into development and through phase 1 and 2 trials. Ray has also held research and development leadership roles at Sanofi, Aventis, Rhone-Poulenc Rorer and Roche, where he developed deep expertise in the fields of inflammation, immunology, and infectious disease. Ray graduated with a PhD in Biochemistry from Cardiff University, followed by a post-doctoral fellowship at the Scripps Research Institute, San Diego.

James Legg

SVP R&ED

James Legg
SVP R&ED
Before joining Mestag James was SVP Research at Crescendo Biologics where he was responsible for managing Crescendo’s Immuno Oncology Portfolio from research through to preclinical development. James has 17 years’ experience in biologics drug discovery, mostly in the oncology area and has been responsible for the successful progression of multiple oncology biologics programmes through the research phases of drug discovery into preclinical development. Prior to joining Crescendo, James was a member of the oncology leadership team at MedImmune, the Biologics arm of AstraZeneca and held key scientific positions at Cambridge Antibody Technology. James has a BSc in Applied Biology from Bath University, a Ph.D in Molecular Cell Biology from Imperial College, London and undertook PostDoctoral research with Fiona Watt at Imperial Cancer Research Fund (now CRUK) in London.

Robert de Jonge

VP Head of Corporate Development

Robert de Jonge
VP Head of Corporate Development
Robert de Jonge is the Head of Corporate Development of Mestag Therapeutics. Robert has broad background in business and corporate development in biotech. He joined Mestag from Cellinta, where he was the Head of Corporate Development. Previously, he was the Head of Business Development at Tusk Therapeutics, an immuno oncology company developing antibody therapeutics for the treatment of cancer. At Tusk, he was responsible for the company’s business development activities. He was closely involved in the sale of Tusk to Roche (€655m, €70m upfront). Robert also served as the Chief Executive Officer of Black Belt Therapeutics; an oncology company focused on targeting the stress response pathways in cancer. Earlier in his career, he worked as the Head of Contract Research for reMYND, a biotech company focused on the development of small molecule therapeutics for the treatment of Alzheimer’s, Parkinson’s and Diabetes. He also worked as an investment analyst at M Ventures, Merck KGaA’s corporate venture capital arm. He holds an MSc in molecular biology and business economics from Leiden University and Delft University of Technology in the Netherlands.

Samantha Macro

VP Head of Finance

Samantha Macro
VP Head of Finance
Samantha is VP, Head of Finance at Mestag Therapeutics. Qualifying as a Chartered Accountant at PwC she spent time in their Cambridge and Brisbane offices. Samantha spent the last 15 years within Life Sciences, initially at Cambridge Antibody Technology - later acquired by AstraZeneca included the integration with MedImmune, where she was part of the leadership teams of three Innovative Medicines Units; Respiratory, Inflammation and Autoimmune; Cardiovascular and Molecular Diseases; and Neuroscience. Samantha then Johnson Matthey Pharma division to support the evolution and strategy of the ex-US region. Prior to joining Mestag, Samantha was the Global Head of Finance for Horizon Discovery Group, supporting the strategic and M&A initiatives while preparing the finance function for a NASDAQ listing, resulting in PerkinElmer acquiring the Group at the end of 2020. Samantha has an MBA and PhD from Loughborough University Business School, latter within the department of International Business and Strategy.

Patrice Love

VP People and Culture

Patrice Love
VP People and Culture